Back to List View Graph View

Enfortumab vedotin

Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC) designed to target Nectin-4 (also known as PVRL4), a cell adhesion molecule overexpressed on the surface of various epithelial tumor cells, most notably in urothelial carcinoma and triple-negative breast cancer.

Where the papers sit

15 papers from the last 6 months study enfortumab vedotin directly · updated from PubMed 14 Nov 2026

  • First-Line Urothelial Cancer

    Enfortumab vedotin plus pembrolizumab is moving into routine first-line care for advanced and metastatic urothelial carcinoma, including very old and poor-performance patients. Real-world cohorts track progression-free survival, complete response, safety, and treatment discontinuation after toxicity or response. Cutaneous events, eosinophil proportion, and structured symptom monitoring recur as priorities for managing treatment. Comparisons with avelumab maintenance and gemcitabine-cisplatin are defining where the combination fits, but durability outside trials remains open.

    9 papers · 60%

  • Bladder Cancer Combination Therapy

    Enfortumab vedotin plus pembrolizumab is being extended across cisplatin-eligible, cisplatin-ineligible, and cisplatin-resistant bladder cancer. Preclinical work links enfortumab vedotin to immunogenic cell death and greater activity with PD-1 blockade. Clinical and economic studies are testing perioperative use alongside standard treatment choices, with cisplatin eligibility shaping selection. Whether these combinations improve survival enough to replace or complement cisplatin-based therapy remains unresolved.

    4 papers · 26.7%

  • Elderly Urothelial Cancer Care

    First-line enfortumab vedotin plus pembrolizumab is being adapted for elderly patients with advanced urothelial carcinoma, while supportive care targets treatment-related skin toxicity. Real-world outcomes emphasize disease progression, follow-up, creatinine, and tolerability in this population. Prophylactic intravenous dexamethasone is associated with fewer cutaneous events, suggesting a practical toxicity-prevention strategy. The evidence remains limited to early observational experience rather than a settled age-specific standard.

    2 papers · 13.3%

PARADIGM SHIFT

Enfortumab vedotin activity is not limited to Nectin-4-rich tumor cells

The cisplatin-resistant bladder cancer model studied by the authors of PMID 42955934 and the preclinical urothelial-cancer models studied by the authors of PMID 42685702 both challenge the assumption that enfortumab vedotin efficacy depends primarily on abundant Nectin-4-mediated targeting. The cisplatin-resistant cells became more sensitive despite reduced surface Nectin-4 expression and weaker drug binding, because increased sensitivity to the MMAE payload and ABCB1-related effects dominated; separately, enfortumab vedotin produced a bystander effect in Nectin-4-negative neighboring cells. The relevant determinants of response therefore extend beyond target abundance to payload handling and cytotoxic effects on surrounding cells.

Papers

The 15 papers from the last 6 months that study enfortumab vedotin directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

First-Line Urothelial Cancer (9)
  1. Structured Symptom Monitoring During Enfortumab Vedotin Plus Pembrolizumab for Advanced or Metastatic Urothelial Carcinoma: Multicenter Retrospective Study. Anticancer research · 1 Oct 2026 PMID 42823162
  2. Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin. Cancer medicine · 2 Sept 2026 PMID 42681561
  3. Clinical Outcomes of Metastatic Urothelial Carcinoma Patients Discontinuing Enfortumab Vedotin Due to Toxicity and/or Clinical Response. Clinical genitourinary cancer · 19 Aug 2026 PMID 42618453
  4. Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study. Anticancer research · 29 Jul 2026 PMID 42527056
  5. Short-term efficacy and safety of enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma regardless of cisplatin eligibility. Japanese journal of clinical oncology · 20 Jul 2026 PMID 42476103
  6. Real-world safety and effectiveness of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: A multicenter Japanese cohort study. Urologic oncology · 17 Jul 2026 PMID 42469056
  7. Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS). Cancer immunology, immunotherapy : CII · 12 Jul 2026 PMID 42437411
  8. First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma. JAMA network open · 1 Jul 2026 PMID 42384383
  9. Real-world Comparison of Avelumab Maintenance and Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma. Anticancer research · 29 Jun 2026 PMID 42373274
Bladder Cancer Combination Therapy (4)
  1. Enhanced enfortumab vedotin sensitivity in a cisplatin-resistant bladder cancer model. PloS one · 29 Oct 2026 PMID 42955934
  2. Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor. Cell reports. Medicine · 2 Sept 2026 PMID 42685702
  3. Cost-effectiveness of perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible or cisplatin-declining patients with muscle-invasive bladder cancer in the United States. Journal of medical economics · 18 Aug 2026 PMID 42610318
  4. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. The New England journal of medicine · 22 Jul 2026 PMID 42485627
Elderly Urothelial Cancer Care (2)
  1. Real-world Outcomes of First-line Enfortumab Vedotin Plus Pembrolizumab in Elderly Patients With Advanced Urothelial Carcinoma. Anticancer research · 1 Oct 2026 PMID 42823175
  2. Prophylactic intravenous dexamethasone is associated with reduced cutaneous toxicity during first-line enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma: a multicenter prospective cohort study. International journal of clinical oncology · 3 Sept 2026 PMID 42687064

By study type

Clinical trials (1)
  1. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. The New England journal of medicine · 22 Jul 2026 PMID 42485627
Observational studies and case reports (10)
  1. Real-world Outcomes of First-line Enfortumab Vedotin Plus Pembrolizumab in Elderly Patients With Advanced Urothelial Carcinoma. Anticancer research · 1 Oct 2026 PMID 42823175
  2. Structured Symptom Monitoring During Enfortumab Vedotin Plus Pembrolizumab for Advanced or Metastatic Urothelial Carcinoma: Multicenter Retrospective Study. Anticancer research · 1 Oct 2026 PMID 42823162
  3. Prophylactic intravenous dexamethasone is associated with reduced cutaneous toxicity during first-line enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma: a multicenter prospective cohort study. International journal of clinical oncology · 3 Sept 2026 PMID 42687064
  4. Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin. Cancer medicine · 2 Sept 2026 PMID 42681561
  5. Clinical Outcomes of Metastatic Urothelial Carcinoma Patients Discontinuing Enfortumab Vedotin Due to Toxicity and/or Clinical Response. Clinical genitourinary cancer · 19 Aug 2026 PMID 42618453
  6. Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study. Anticancer research · 29 Jul 2026 PMID 42527056
  7. Short-term efficacy and safety of enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma regardless of cisplatin eligibility. Japanese journal of clinical oncology · 20 Jul 2026 PMID 42476103
  8. Real-world safety and effectiveness of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: A multicenter Japanese cohort study. Urologic oncology · 17 Jul 2026 PMID 42469056
  9. First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma. JAMA network open · 1 Jul 2026 PMID 42384383
  10. Real-world Comparison of Avelumab Maintenance and Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma. Anticancer research · 29 Jun 2026 PMID 42373274
Human data, design not indexed (1)
  1. Cost-effectiveness of perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible or cisplatin-declining patients with muscle-invasive bladder cancer in the United States. Journal of medical economics · 18 Aug 2026 PMID 42610318
Preclinical: animal, cell and lab studies (2)
  1. Enhanced enfortumab vedotin sensitivity in a cisplatin-resistant bladder cancer model. PloS one · 29 Oct 2026 PMID 42955934
  2. Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor. Cell reports. Medicine · 2 Sept 2026 PMID 42685702
Unclassified: not yet indexed with MeSH (1)
  1. Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS). Cancer immunology, immunotherapy : CII · 12 Jul 2026 PMID 42437411